비외상성 의식 변화 환자의 기질적 원인과 비기질적 원인의 감별에 있어 혈청 S-100B 단백질과 신경특이에놀레이즈 검사의 유용성 = The Usefulness of Serum S-100B Protein and Neuron-Specific Enolase as a Screening Test for Making the Differential Diagnosis of Patients with Non-Traumatic Altered Mentality

다국어 초록 (Multilingual Abstract)

Purpose: There are so many causes of an altered mental status, including acute stroke and nonorganic causes.
Making the differential diagnosis and the diagnostic approach for cases with an altered mental status represent a challenge to all emergency physicians. The serum S-100B protein concentration and the neuron-specific enolase (NSE) concentration have been used to evaluate brain damaged patients. We evaluated the usefulness of the serum S-100B protein concentration and the NSE concentration as screening tests for the patients with an altered mentality Methods: Seventy-eight patients with an altered mentality were included in this prospective study. The patients were divided in two groups. One was the acute stroke group and the other was the non-organic cause group. We analyzed the serum S-100B protein and NSE concentrations of the two groups. We also assessed the correlation of the serum S-100B protein and NSE concentrations with the clinical and laboratory data of the two groups Results: The serum concentration of S-100B was higher in the acute stroke group (median: 0.376, interquartile range: 0.18-1.05) than that in the nonorganic group (0.123, 0.087- 0.307, p=0.000). The NSE level was also higher in the acute stroke group (median: 19.12, interquartile range: 14.42-27.19) than that in the non-organic group (13.71, 10.48-19.29, p=0.002). To differentiate the acute stroke group from the non-organic group, the sensitivity and specificity was 81.1% and 61.0%, respectively, at a cutoff value for the serum S-100B protein concentration of 0.14 μg/L, and these were 81.1% and 51.2%, respectively, at a cutoff value for the serum NSE concentration of 13.71 μg/L Conclusion: Our study suggests that the serum S-100B protein and NSE concentrations may be useful as screening markers for differentiating acute stroke from non-organic causes.
However, further studies are needed to evaluate the relationship between the two proteins and the various diseases that have possibility to alter patients' mental status before these two proteins can be used clinically as screening tests.

참고문헌 (Reference)

1 박맹렬, "국소 신경학적 장애가 동반되지 않은 급성 뇌중풍 환자에서S-100B 단백의 유용성" 대한응급의학회 19 (19): 82-87, 2008

2 Marx JA, "Walls RM. Rosen’s Emergency Medicine. Concepts and clinical practice. 6th ed" Mosby 156-164, 2006

3 Selakovic V, "The increase of neuron-specific enolase in cerebrospinal fluid and plasma as a marker of neuronal damage in patients with acute brain infarction" 12 : 542-547, 2005

4 Buttner T, "Serum levels of neuron-specific enolase and s-100 protein after single tonic-clonic seizures" 246 : 459-461, 1999

5 Strauss GI, "S-100b and neuron-specific enolase in patients with fulminant hepatic failure" 7 : 964-970, 2001

6 Isobe T, "S-100a0 protein is present in neurons of central and peripheral nervous system" 43 : 1494-1496, 1984

7 Oertel M, "S-100B and NSE: markers of initial impact of subarachnoid haemorrhage and their relation to vasospasm and outcome" 13 : 834-840, 2006

8 Missler U, "S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke" 28 : 1956-1960, 1997

9 Persson L, "S-100 protein and neuron- specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system" 18 : 911-918, 1987

10 Townend W, "Rapid elimination of protein S-100B from serum after minor head trauma" 23 : 149-155, 2006

11 Marchi N, "Peripheral markers of brain damage and blood-brain barrier dysfunction" 21 : 109-121, 2003

12 Tapia FJ, "Neuron-specific enolase is produced by neuroendocrine tumours" 1 : 808-811, 1981

13 Marangos PJ, "Measurement of neuron-specific (NSE) and non-neuronal (NNE) isoenzymes of enolase in rat, monkey and human nervous tissue" 33 : 319-329, 1979

14 Routsi C, "Increased levels of serum S100B protein in critically ill patients without brain injury" 26 : 20-24, 2006

15 Szem JW, "High-risk intrahospital transport of critically ill patients: safety and outcome of the necessary “road trip”" 23 : 1660-1666, 1995

16 Kato K, "Distribution of nervous system-specific forms of enolase in peripheral tissues" 237 : 441-448, 1982

17 Johnson J, "Differential diagnosis of dementia, delirium and depression: implication for drug therapy" 5 : 431-445, 1994

18 Oh EJ, "Diagnostic value of elecsys S100 as a marker of acute brain injury in the emergency department" 21 : 387-392, 2007

19 Erkinjuntti T, "Dementia among medical inpatients: evaluation of 2000 consecutive admissions" 146 : 1923-1926, 1986

20 Wu YC, "Correlation between serum level of neuron-specific enolase and longterm functional outcome after acute cerebral infarction: prospective study" 10 : 251-254, 2004

21 American College of Emergency Physicians, "Clinical policy for the initial approach to patients presenting with altered mental status" 33 : 251-281, 1999

22 Endo T, "Calcium dependent affinity chromatography of S-100 and calmodulin on calmodulin antagonist coupled Sepharose" 256 : 12485-12489, 1981

23 Kekec Z, "Analysis of altered mental status in Turkey" 118 : 609-617, 2008

24 Kanich W, "Altered mental status: evaluation and etiology in the ED" 20 : 613-617, 2002

25 Sulkowski JA, "Acute mental status changes" 8 : 319-334, 1997

26 Wofford JL, "Acute cognitive impairment in elderly ED patients: etiologies and outcomes" 14 : 649-653, 1996